1. Home
  2. PPC vs SYRE Comparison

PPC vs SYRE Comparison

Compare PPC & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pilgrim's Pride Corporation

PPC

Pilgrim's Pride Corporation

HOLD

Current Price

$28.58

Market Cap

7.2B

ML Signal

HOLD

Logo Spyre Therapeutics Inc.

SYRE

Spyre Therapeutics Inc.

HOLD

Current Price

$100.80

Market Cap

6.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PPC
SYRE
Founded
1946
2013
Country
United States
United States
Employees
52100
N/A
Industry
Meat/Poultry/Fish
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2B
6.5B
IPO Year
1997
2015

Fundamental Metrics

Financial Performance
Metric
PPC
SYRE
Price
$28.58
$100.80
Analyst Decision
Hold
Strong Buy
Analyst Count
3
12
Target Price
$41.33
$85.08
AVG Volume (30 Days)
1.5M
1.3M
Earning Date
04-29-2026
05-08-2026
Dividend Yield
6.74%
N/A
EPS Growth
N/A
N/A
EPS
0.43
N/A
Revenue
$18,497,553,000.00
N/A
Revenue This Year
$2.46
N/A
Revenue Next Year
$1.83
N/A
P/E Ratio
$64.93
N/A
Revenue Growth
3.46
N/A
52 Week Low
$26.50
$14.51
52 Week High
$50.56
$105.09

Technical Indicators

Market Signals
Indicator
PPC
SYRE
Relative Strength Index (RSI) 50.35 58.38
Support Level $27.02 $92.37
Resistance Level $29.73 $103.58
Average True Range (ATR) 0.96 6.01
MACD 0.05 -0.21
Stochastic Oscillator 57.79 73.99

Price Performance

Historical Comparison
PPC
SYRE

About PPC Pilgrim's Pride Corporation

Pilgrim's Pride is the second-largest poultry producer in the US (59% of 2024 sales), the UK (29% including other European sales), and Mexico (12%). Its UK and European arm also includes pork operations from the 2019 acquisition of Tulip. Pilgrim's sells to chain restaurants, food processors, food distributors, and retail chains. Most of its US and Mexican sales come from fresh chicken, while prepared chicken and pork constitute most of its UK and European sales. JBS owns more than 80% of Pilgrim's Pride's outstanding shares, though it failed to acquire the remaining stake in 2021 after a special board committee deemed JBS's offer undervalued Pilgrim's Pride.

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Share on Social Networks: